RPRita Peila

Rita Peila

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rita Peila has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Lenore J. Launer

    4 shared publications
  • Lon R. White

    3 shared publications
  • Beatriz L. Rodriguez

    From the Laboratory of Epidemiology, Demography and Biometry (Drs. Peila and Launer), National Institute on Aging, National Institutes of Health, Bethesda, MD; Clinical Epidemiology and Geriatric Division (Drs. Rodriguez and White), Department of Medicine, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu; and Pacific Health Research Institute (Dr. White), Manoa, Honolulu, HI

    2 shared publications
  • Helen Petrovitch

    2 shared publications
  • Berran Yucesoy

    1 shared publication
  • G.W. Ross

    From the Epidemiology, Demography and Biometry Program, National Institute on Aging, National Institutes of Health, Bethesda, Md (R.P., R.J.H., L.J.L.), and the Pacific Health Research Institute (L.R.W., H.P., K.M.) and Department of Veteran’s Affairs (G.W.R.), Honolulu, Hawaii

    1 shared publication

Latest Publications

  • A TGF-β1 polymorphism association with dementia and neuropathologies: The HAAS

    by Rita Peila, Berran Yucesoy, Lon R. White, Victor Johnson, Michael L. Kashon, Kim Wu, Helen Petrovitch, Michael Luster, Lenore J. Launer


  • Reducing the Risk of Dementia

    by Rita Peila, Lon R. White, Kamal Masaki, Helen Petrovitch, Lenore J. Launer

    Background and Purpose— The efficacy of treating older persons for hypertension remains controversial. Although clinical trials suggest no short-term harm, or some benefits, there are little data on the effect on cognitive function of long-term antihypertensive treatment. We evaluated the risk of dementia and cognitive decline associated with duration of antihypertensive treatment. Methods— Data are from the Honolulu Asia Aging Study on Japanese American men followed since 1965. The subjects included in this analysis were hypertensive from midlife and dementia-free in 1991 (mean age 76.7 years). In 1991, 1994 and 1997, global cognitive function was assessed with the Cognitive Abilities Screening Instrument (CASI) and dementia by a standardized examination using international criteria. The sample was grouped by treatment duration (never-treated hypertensives (NTH), 12 years). Normotensive subjects up to 1991 were included in the analysis as a control group. Results— For each additional year of treatment there was a reduction in the risk of incident dementia (hazard ratio [HR]=0.94, 95% CI, 0.89 to 0.99). The risk for dementia in subjects with >12 years of treatment was lower compared to NTH (HR for dementia=0.40; 95% CI, 0.22 to 0.75 and for Alzheimer disease HR=0.35; 95% CI, 0.16 to 0.78) and was similar to the normotensives. Nondemented subjects with 5 to 12 years of treatment had lower yearly CASI decline compared to NTH. Conclusions— Results suggest that in hypertensive men, the duration of the antihypertensive treatment is associated with a reduced risk for dementia and cognitive decline.


  • Fasting insulin and incident dementia in an elderly population of Japanese-American men

    by Rita Peila, Beatriz L. Rodriguez, Lon R. White, Lenore J. Launer

    Objective: To evaluate the association of fasting insulin level to incident dementia in a cohort of elderly men. Methods: Data are from the Honolulu-Asia Aging Study, a community-based study of Japanese-American men, aged 71 to 91 years in 1991. Serum insulin was measured in 1991 and participants were grouped based on their insulin levels. Dementia was ascertained in 1991, 1994, and 1996 according to international guidelines. The 2,568 men dementia-free in 1991 were reexamined in 1994 and 1996; 244 new cases of dementia were diagnosed. Survival analysis with age as the time scale was used to estimate the risk (hazard ratio [HR] and 95% CI) for incident dementia associated with levels of insulin. Results: The risk of dementia was increased at the two extremes of the insulin distribution (lower and upper 15th percentiles). Compared to the rest of the cohort subjects in the lowest 15th percentile and highest 15th percentile had an increased risk for dementia (HR = 1.54, CI 1.11 to 2.11 and HR = 1.54, CI 1.05 to 2.26). In men with insulin levels Conclusions: Both low and high levels of insulin are associated with an increased risk of developing dementia.


  • Top Cited Papers

    Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies

    by Rita Peila, Beatriz L. Rodriguez, Lenore J. Launer, Honolulu-Asia Aging Study

    Type 2 diabetes may be a risk factor for dementia, but the associated pathological mechanisms remains unclear. We evaluated the association of diabetes alone or combined with the apolipoprotein E (APOE) gene with incident dementia and neuropathological outcomes in a population-based cohort of 2,574 Japanese-American men enrolled in the Honolulu-Asia Aging Study, including 216 subjects who underwent autopsy. Type 2 diabetes was ascertained by interview and direct glucose testing. Dementia was assessed in 1991 and 1994 by clinical examination and magnetic resonance imaging and was diagnosed according to international guidelines. Logistic regression was used to assess the RR of developing dementia, and log-linear regression was used to estimate the incident rate ratio (IRR) of neuropathological outcomes. Diabetes was associated with total dementia (RR 1.5 [95% CI 1.01–2.2]), Alzheimer’s disease (AD; 1.8 [1.1–2.9]), and vascular dementia (VsD; 2.3 [1.1–5.0]). Individuals with both type 2 diabetes and the APOE ε4 allele had an RR of 5.5 (CI 2.2–13.7) for AD compared with those with neither risk factor. Participants with type 2 diabetes and the ε4 allele had a higher number of hippocampal neuritic plaques (IRR 3.0 [CI 1.2–7.3]) and neurofibrillary tangles in the cortex (IRR 3.5 [1.6–7.5]) and hippocampus (IRR 2.5 [1.5–3.7]), and they had a higher risk of cerebral amyloid angiopathy (RR 6.6, 1.5–29.6). Type 2 diabetes is a risk factor for AD and VsD. The association between diabetes and AD is particularly strong among carriers of the APOE ε4 allele. The neuropathological data are consistent with the clinical results.


  • Joint Effect of the APOE Gene and Midlife Systolic Blood Pressure on Late-Life Cognitive Impairment

    by R. Peila, L.R. White, H. Petrovich, K. Masaki, G.W. Ross, R.J. Havlik, L.J. Launer

    Background and Purpose — The aim of this study was to explore the joint effect of the APOE ε4 allele and midlife systolic blood pressure (SBP) on the risk for poor cognitive function in late life. Methods — The study includes 3605 surviving members of the cohort of the Japanese-American men followed prospectively over 26 years (1965–1991) as a part of the Honolulu Heart Program. In 1965 men were aged 45 to 68 years and were living in the island of Oahu, Hawaii. For this study the sample was divided into 4 categories: normal SBP ( Results — After adjusting for age, education, smoking, alcohol use, and body mass index, the RR for poor cognitive function (CASI Conclusions — The results suggest that midlife high SBP has a stronger adverse effect on cognitive function in persons with higher genetic susceptibility, but this effect may be modified by antihypertensive treatment.